Loading
GH
Gelesis Holdings, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by KUCHERLAPATI RAJU S, was filed 22 Nov 2022.
Gelesis Holdings, Inc.: what insiders have been doing
Every trade that managers of Gelesis Holdings, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Gelesis Holdings, Inc. has had no insider filing for more than a year; the last one goes back to 22 November 2022.
Our records for Gelesis Holdings, Inc. go back to 2020, with 5 purchases and no sales on the open market in total.
In the same sector, recent insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
33
Thresholds
n/a
Buy Volume
€176,266
5 ops. · all time
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$22.2M
Net income-US$48M-216.5% margin
Last declaration on 22 November 2022
Declarations33 total
92,000 shares@ US$0.4522.7% of flowCommon StockSEC:0001562180-22-007835:1
Canonical exit: 19 Feb 2023 (T+90)
8,000 shares@ US$0.392.2% of flowCommon StockSEC:0001562180-22-007835:0
Canonical exit: 16 Feb 2023 (T+90)
24,625 shares@ US$1.947133.7% of flowCommon StockSEC:0001562180-22-005171:0
Canonical exit: 13 Sept 2022 (T+90)
80,500 sharesCommon StockSEC:0001562180-22-005012:0
39,922 sharesCommon StockSEC:0001104659-22-057541:1
431,456 sharesCommon StockSEC:0001104659-22-057541:2
148,313 sharesCommon StockSEC:0001104659-22-057527:1
34,266 sharesCommon StockSEC:0001104659-22-057537:1
269,660 sharesCommon StockSEC:0001104659-22-057537:2
48,869 sharesCommon StockSEC:0001104659-22-057548:1
898,867 sharesCommon StockSEC:0001104659-22-057548:2
233,705 sharesCommon StockSEC:0001104659-22-057525:1
31,392 sharesCommon StockSEC:0001104659-22-057539:1
395,501 sharesCommon StockSEC:0001104659-22-057539:2
50,639 sharesCommon StockSEC:0001104659-22-057534:0
11,841 sharesCommon StockSEC:0001104659-22-057541:0
51,095 sharesCommon StockSEC:0001104659-22-057518:0
22,732 sharesCommon StockSEC:0001104659-22-057525:0
5,082 sharesCommon StockSEC:0001104659-22-057539:0
10,164 sharesCommon StockSEC:0001104659-22-057537:0
49,270 sharesCommon StockSEC:0001104659-22-057542:0
50,182 sharesCommon StockSEC:0001104659-22-057547:0
34,266 sharesCommon StockSEC:0001104659-22-057527:0
53,832 sharesCommon StockSEC:0001104659-22-057532:0
68,966 sharesCommon StockSEC:0001104659-22-057545:0
25 of 33 declarations
About Gelesis Holdings, Inc.
Gelesis Holdings, Inc. is a U.S.-listed biotherapeutics company that has traded on the NYSE under the symbol GLS, making it part of the U.S. public market universe relevant to NYSE/NASDAQ investors. The company’s business has centered on a proprietary hydrogel technology designed to work mechanically in the gastrointestinal tract rather than through a systemic chemical mechanism. In practical terms, Gelesis has aimed to address obesity and weight management with an oral, non-systemic approach that differentiates it from many conventional prescription therapies.
The company traces its roots to Gelesis, Inc., a life-sciences venture built over several years through private financing rounds and clinical development work before becoming a public company. Its headquarters are in Boston, Massachusetts, United States, placing it in one of the strongest biotech clusters in North America. Historically, the organization has been best known for Plenity, its lead product, which was designed as an oral hydrogel-based aid intended to increase feelings of fullness and support weight loss in certain overweight and obese adults. Earlier pipeline references also included programs such as Gelesis100 and Gelesis200, although investors should treat historical pipeline mentions carefully because development priorities, regulatory status, and commercialization plans can change.
Read moreShow less
From a competitive standpoint, Gelesis operates in a highly competitive obesity-treatment market. It faces established pharmaceutical players, emerging GLP-1-based therapies, device-oriented solutions, and broader wellness platforms. Its main differentiator is the attempt to offer a non-systemic, orally administered alternative that may appeal to patients and clinicians looking for a different risk-benefit profile than injectable anti-obesity drugs. That said, differentiation alone does not eliminate the challenges of reimbursement, physician adoption, commercial scaling, or capital intensity.
Geographically, the company’s core commercial footprint has been concentrated in the United States, though its historical communications indicated interest in regulatory and commercial opportunities abroad. Recent milestones that matter for investors include the business combination with Capstar, the corporate rename to Gelesis Holdings, Inc., the NYSE listing process, and subsequent market and compliance developments. For French-speaking investors, Gelesis should be viewed as a speculative healthcare equity with meaningful execution risk, where valuation is likely to depend on product adoption, intellectual property, financing capacity, and the company’s ability to build a sustainable commercial model in the United States and potentially beyond.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
